Home Menu

Seasonal Flu Vaccine Offers 2018-19

NHS England has released its ‘definitive’ guidance for GP practices about which flu vaccines to use for the 2018-19 season.

NHS England is now advising all practices to use the adjuvanted trivalent vaccine (Fluad - Seqirus) for all patients over 65 and a quadrivalent vaccine for any ‘at risk’ groups including pregnant women aged 18-65 years.

This decision has been based on clinical evidence from the Joint Committee on Vaccination and Immunisation (JCVI) and cost effectiveness studies by Public Health England.

Suppliers of the adjuvanted trivalent and quadrivalent vaccines have given NHS England assurances that they will be able to cope with the increased demand for their vaccines.

Additional funding has been found to cover the additional costs of using the adjuvanted trivalent and quadrivalent vaccines, so practices do not need to worry about not being reimbursed.

Please note that practices will still need to order trivalent vaccines for any at risk patients age six months to two years as Fluenz, Fluad and quadrivalent vaccines aren’t licensed for this age group. MASTA, Mylan and Seqirus can provide vaccines suitable for children age six months and above. For more information on these discounts, please visit our website.

As this definitive guidance was released after most practices would have placed their vaccine order with their preferred supplier, we have spoken with the four companies we negotiated discounts with for the 2018-19 season to compile advice for those practices that now need to cancel or amend their original vaccine orders (see next pages).

If you have any questions, please call us on 0115 979 6910, email info@lmcbuyinggroups.co.uk or Live Chat with us via the website: https://www.lmcbuyinggroups.co.uk/.

To have full access to the website and the Buying Group discounts and service, please complete the registration form on the website: https://www.lmcbuyinggroups.co.uk/members/.


Please click on the document attached at the top of the page for further information.